Supplier
Winchester Medical Center
Winchester Medical Center was paid $69.83M by Medicaid between Jan 2018 and Dec 2024, across 407 billing codes. Its largest line is 99285, emergency room visit (most serious) — 14% of everything it billed.
33Billing provider infoWINCHESTER MEDICAL CENTER
WINCHESTER, VA 22601
WINCHESTER, VA 22601
33aNPI1619928017assigned 05/12/2006
33bProvider typeDurable Medical Equipment & Medical Supplies
28Total paid$69.83M
24GClaims1,435,792
24DCodes billed407
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Durable Medical Equipment & Medical Supplies providers in Virginia
Rank by total paid#2 of 229
Median peer was paid$17K
This provider vs. median4,227×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 162,643 | $6.99M | |
| 2019 | 195,559 | $8.54M | |
| 2020 | 189,480 | $8.76M | |
| 2021 | 215,899 | $9.62M | |
| 2022 | 211,831 | $10.58M | |
| 2023 | 247,845 | $12.30M | |
| 2024incomplete | 212,535 | $13.04M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 14% | 45,653 | 39,865 | $9.65M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 7.8% | 29,340 | 26,091 | $5.42M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 7.7% | 32,896 | 29,693 | $5.37M |
| 96361 | Intravenous infusion, hydration; each additional hour | 6.7% | 19,217 | 15,172 | $4.65M |
| 41899 | Unlisted procedure, dentoalveolar structures | 5.8% | 3,066 | 2,822 | $4.06M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 3.5% | 8,897 | 8,303 | $2.44M |
| G0378 | Hospital observation service, per hour | 2.6% | 12,322 | 9,868 | $1.78M |
| 70450 | Computed tomography, head or brain; without contrast material | 2.2% | 9,457 | 8,628 | $1.55M |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 2.0% | 20,776 | 6,595 | $1.39M |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | 1.6% | 2,229 | 2,144 | $1.10M |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 1.4% | 3,925 | 3,659 | $999K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.3% | 6,010 | 4,306 | $894K |
395 more codes
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | 1.3% | 1,350 | $879K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | 1.2% | 5,552 | $854K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 1.2% | 28,753 | $837K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | 1.1% | 14,303 | $778K |
| 71275 | Computed tomographic angiography, chest, with contrast material | 1.1% | 3,317 | $778K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 1.1% | 5,189 | $757K |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | 1.1% | 9,689 | $743K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | 1.0% | 10,449 | $721K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 1.0% | 15,480 | $705K |
| 36415 | Collection of venous blood by venipuncture | 1.0% | 93,863 | $705K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 2,281 | $696K |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 1,249 | $692K |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 1,055 | $650K |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 9,181 | $606K |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | <1% | 842 | $599K |
| 49083 | <1% | 1,232 | $585K | |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 7,891 | $569K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 2,803 | $553K |
| A4216 | Sterile water, saline and/or dextrose, diluent/flush, 10 ml | <1% | 3,084 | $544K |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 2,132 | $509K |
| 76819 | Fetal biophysical profile; without non-stress testing | <1% | 5,473 | $493K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 2,311 | $453K |
| 76811 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation, detailed | <1% | 4,287 | $436K |
| 97161 | <1% | 4,468 | $433K | |
| 43235 | <1% | 929 | $423K | |
| 59025 | Fetal non-stress test | <1% | 2,253 | $405K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 23,411 | $361K |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 6,121 | $352K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 89,060 | $331K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 3,569 | $326K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 3,530 | $319K |
| 80053 | Comprehensive metabolic panel | <1% | 50,558 | $315K |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 963 | $303K |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 1,118 | $277K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 1,391 | $255K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 35,997 | $241K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 33,269 | $224K |
| 76770 | <1% | 1,936 | $223K | |
| 93971 | <1% | 2,432 | $215K | |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | <1% | 309 | $204K |
| J2704 | Injection, propofol, 10 mg | <1% | 15,767 | $201K |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 15,555 | $200K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 14,070 | $195K |
| 78815 | Positron emission tomography (PET) for limited area imaging | <1% | 262 | $190K |
| G0330 | Facility services for dental rehabilitation procedure(s) performed on a patient who requires monitored anesthesia (e.g., general, intravenous sedation (monitored anesthesia care) and use of an operating room | <1% | 105 | $189K |
| 29581 | <1% | 1,318 | $188K | |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 1,596 | $185K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 3,071 | $183K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 19,100 | $181K |
| S9480 | Intensive outpatient psychiatric services, per diem | <1% | 775 | $181K |
| 96376 | <1% | 11,849 | $179K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 8,396 | $176K |
| 93325 | <1% | 1,135 | $171K | |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 4,518 | $170K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 6,247 | $152K |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 10,202 | $148K |
| 76801 | <1% | 3,359 | $147K | |
| 80047 | <1% | 14,734 | $141K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 1,783 | $137K |
| 77386 | <1% | 414 | $135K | |
| 76830 | Ultrasound, transvaginal | <1% | 1,279 | $132K |
| J3490 | Unclassified drugs | <1% | 23,913 | $128K |
| 76641 | <1% | 1,136 | $126K | |
| 71250 | <1% | 1,887 | $126K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 13,115 | $126K |
| 93017 | <1% | 1,529 | $122K | |
| P9047 | Infusion, albumin (human), 25%, 50 ml | <1% | 291 | $119K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 2,168 | $118K |
| 97165 | <1% | 1,738 | $115K | |
| 76813 | <1% | 1,205 | $110K | |
| 77336 | <1% | 1,386 | $109K | |
| 69436 | Tympanostomy (requiring insertion of ventilating tube), general anesthesia | <1% | 94 | $109K |
| 77412 | <1% | 278 | $99K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 1,662 | $99K |
| 93970 | <1% | 839 | $95K | |
| 83880 | <1% | 6,786 | $93K | |
| 82948 | <1% | 17,609 | $90K | |
| 84484 | <1% | 23,147 | $89K | |
| 80061 | Lipid panel | <1% | 8,734 | $89K |
| 86901 | <1% | 4,831 | $89K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 4,295 | $89K |
| C1769 | Guide wire | <1% | 3,376 | $84K |
| 81001 | <1% | 28,402 | $76K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 2,664 | $74K |
| 97602 | <1% | 657 | $72K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 14,288 | $71K |
| 97116 | <1% | 2,260 | $69K | |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 6,408 | $67K |
| 93925 | <1% | 756 | $67K | |
| 76820 | <1% | 1,389 | $66K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 8,931 | $63K |
| 73610 | <1% | 2,822 | $62K | |
| 97162 | <1% | 639 | $60K | |
| 85610 | <1% | 15,000 | $55K | |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 1,302 | $54K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 13,056 | $54K |
| 73502 | <1% | 2,248 | $54K | |
| G0108 | Diabetes outpatient self-management training services, individual, per 30 minutes | <1% | 1,142 | $53K |
| 74018 | <1% | 2,381 | $53K | |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | <1% | 2,541 | $53K |
| 73564 | <1% | 2,867 | $52K | |
| 73630 | <1% | 2,214 | $51K | |
| 72110 | <1% | 1,106 | $51K | |
| 87420 | <1% | 2,613 | $51K | |
| 71045 | Radiologic examination, chest; single view | <1% | 10,817 | $49K |
| 73030 | <1% | 2,482 | $48K | |
| 76642 | <1% | 480 | $48K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 4,155 | $47K |
| 12001 | <1% | 194 | $45K | |
| 85379 | <1% | 5,685 | $44K | |
| 77066 | Tomosynthesis, mammo | <1% | 750 | $44K |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 748 | $44K |
| C1887 | Catheter, guiding (may include infusion/perfusion capability) | <1% | 106 | $44K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 5,451 | $43K |
| 72100 | <1% | 2,496 | $43K | |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 1,254 | $43K |
| 87040 | <1% | 3,621 | $42K | |
| 76536 | <1% | 398 | $42K | |
| 83690 | <1% | 11,023 | $41K | |
| 52356 | <1% | 13 | $41K | |
| 80076 | <1% | 6,304 | $40K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 8,117 | $40K |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 8,042 | $38K |
| 87070 | <1% | 3,569 | $36K | |
| 76825 | <1% | 451 | $36K | |
| 73130 | <1% | 1,626 | $36K | |
| 72141 | <1% | 221 | $34K | |
| 84703 | <1% | 11,752 | $34K | |
| 76818 | <1% | 298 | $32K | |
| 74019 | <1% | 987 | $32K | |
| 70496 | <1% | 151 | $30K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 2,204 | $30K |
| 84702 | <1% | 5,390 | $30K | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 8,013 | $30K |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 1,831 | $30K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 11,269 | $29K |
| 84112 | <1% | 1,010 | $29K | |
| 82947 | <1% | 5,547 | $28K | |
| 71271 | <1% | 261 | $28K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 12,057 | $28K |
| 83735 | <1% | 11,147 | $27K | |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | <1% | 1,372 | $27K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 1,289 | $27K |
| 97597 | <1% | 821 | $26K | |
| 83970 | <1% | 1,095 | $26K | |
| 90853 | Group psychotherapy (other than of a multiple-family group) | <1% | 172 | $26K |
| 92609 | <1% | 568 | $25K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 2,201 | $25K |
| 73110 | <1% | 1,125 | $25K | |
| 97113 | <1% | 405 | $24K | |
| 87634 | <1% | 1,062 | $24K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 5,260 | $24K |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 5,732 | $23K |
| 88341 | <1% | 627 | $23K | |
| 66984 | Extracapsular cataract removal with insertion of intraocular lens prosthesis | <1% | 15 | $23K |
| 85027 | <1% | 3,684 | $22K | |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | <1% | 895 | $22K |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 5,534 | $22K |
| 77334 | <1% | 90 | $22K | |
| 82607 | <1% | 3,079 | $21K | |
| J1815 | Injection, insulin, per 5 units | <1% | 1,466 | $21K |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 5,586 | $21K |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | <1% | 2,677 | $21K |
| 86140 | <1% | 6,036 | $21K | |
| 70491 | <1% | 109 | $20K | |
| S0020 | Injection, bupivicaine hydrochloride, 30 ml | <1% | 1,521 | $20K |
| 81025 | <1% | 3,260 | $20K | |
| 72040 | <1% | 820 | $20K | |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | <1% | 320 | $20K |
| 93880 | <1% | 240 | $19K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 5,931 | $19K |
| 86618 | <1% | 1,452 | $19K | |
| 76827 | <1% | 465 | $19K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 871 | $19K |
| 88342 | <1% | 1,343 | $19K | |
| 97163 | <1% | 201 | $18K | |
| 77065 | Tomosynthesis, mammo | <1% | 371 | $18K |
| 85652 | <1% | 4,734 | $17K | |
| 87077 | <1% | 2,991 | $17K | |
| 81003 | <1% | 5,479 | $17K | |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | <1% | 1,129 | $17K |
| 84439 | <1% | 3,330 | $17K | |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | <1% | 243 | $16K |
| 73590 | <1% | 901 | $16K | |
| 85730 | <1% | 5,268 | $16K | |
| 82746 | <1% | 2,512 | $15K | |
| 76870 | <1% | 159 | $15K | |
| 12011 | <1% | 52 | $14K | |
| 93458 | <1% | 12 | $14K | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 6,591 | $14K |
| 82728 | <1% | 2,262 | $14K | |
| 82565 | <1% | 1,913 | $14K | |
| 86850 | <1% | 4,181 | $13K | |
| 94060 | <1% | 324 | $13K | |
| 88304 | <1% | 971 | $13K | |
| 82803 | <1% | 2,050 | $13K | |
| A4217 | Sterile water/saline, 500 ml | <1% | 1,007 | $13K |
| 84466 | <1% | 2,254 | $13K | |
| 94660 | <1% | 51 | $12K | |
| 87081 | <1% | 5,111 | $12K | |
| 86900 | <1% | 4,831 | $11K | |
| 83605 | <1% | 3,781 | $11K | |
| 80074 | <1% | 352 | $11K | |
| 84550 | <1% | 2,251 | $11K | |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 58 | $11K |
| 93922 | <1% | 263 | $11K | |
| 93660 | <1% | 71 | $10K | |
| 94726 | <1% | 176 | $10K | |
| 86803 | <1% | 1,172 | $10K | |
| 80143 | <1% | 2,477 | $10K | |
| 94729 | <1% | 203 | $10K | |
| 87186 | <1% | 4,806 | $10K | |
| 87301 | <1% | 2,505 | $10K | |
| A9575 | Injection, gadoterate meglumine, 0.1 ml | <1% | 2,001 | $10K |
| 70498 | <1% | 181 | $10K | |
| 93010 | Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | <1% | 1,849 | $9K |
| 97166 | <1% | 109 | $9K | |
| 87205 | <1% | 3,100 | $9K | |
| 84100 | <1% | 4,621 | $8K | |
| 10061 | <1% | 58 | $8K | |
| 83540 | <1% | 2,375 | $8K | |
| 87046 | <1% | 661 | $7K | |
| 82570 | <1% | 2,745 | $7K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 1,419 | $7K |
| C8929 | Transthoracic echocardiography with contrast, or without contrast followed by with contrast, real-time with image documentation (2d), includes m-mode recording, when performed, complete, with spectral doppler echocardiography, and with color flow doppler echocardiography | <1% | 27 | $7K |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | <1% | 24 | $7K |
| J3535 | Drug administered through a metered dose inhaler | <1% | 897 | $7K |
| 93351 | <1% | 16 | $7K | |
| 10005 | <1% | 12 | $7K | |
| 76821 | <1% | 124 | $6K | |
| 82550 | <1% | 2,522 | $6K | |
| S0119 | Ondansetron, oral, 4 mg (for circumstances falling under the medicare statute, use hcpcs q code) | <1% | 2,247 | $6K |
| 70486 | <1% | 172 | $6K | |
| G0379 | Direct admission of patient for hospital observation care | <1% | 264 | $6K |
| 87045 | <1% | 530 | $6K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 971 | $6K |
| 84145 | <1% | 673 | $6K | |
| 97012 | <1% | 190 | $6K | |
| 12002 | <1% | 26 | $6K | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 3,100 | $6K |
| 95806 | <1% | 39 | $6K | |
| 88307 | <1% | 124 | $5K | |
| 73090 | <1% | 385 | $5K | |
| 97167 | <1% | 77 | $5K | |
| 73080 | <1% | 318 | $5K | |
| 73140 | <1% | 261 | $5K | |
| 80179 | <1% | 2,278 | $5K | |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 2,285 | $5K |
| J2785 | Injection, regadenoson, 0.1 mg | <1% | 228 | $5K |
| 72131 | <1% | 80 | $4K | |
| 92610 | <1% | 42 | $4K | |
| J8540 | Dexamethasone, oral, 0.25 mg | <1% | 666 | $4K |
| 87340 | <1% | 867 | $4K | |
| 43249 | <1% | 12 | $4K | |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 470 | $4K |
| M0247 | Intravenous infusion, sotrovimab, includes infusion and post administration monitoring | <1% | 15 | $4K |
| J2060 | Injection, lorazepam, 2 mg | <1% | 1,894 | $4K |
| 76937 | <1% | 244 | $4K | |
| 92523 | <1% | 30 | $4K | |
| 85018 | <1% | 1,582 | $4K | |
| 80069 | <1% | 929 | $4K | |
| 87210 | <1% | 804 | $4K | |
| 74183 | <1% | 12 | $4K | |
| 84156 | <1% | 2,224 | $4K | |
| 85014 | <1% | 2,391 | $4K | |
| 86592 | <1% | 577 | $3K | |
| 93976 | <1% | 41 | $3K | |
| 73552 | <1% | 122 | $3K | |
| 95886 | <1% | 61 | $3K | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 1,715 | $3K |
| 87088 | <1% | 1,270 | $3K | |
| 93000 | <1% | 703 | $3K | |
| 36600 | <1% | 363 | $3K | |
| 85007 | <1% | 887 | $2K | |
| 36430 | <1% | 31 | $2K | |
| 29125 | <1% | 71 | $2K | |
| 77300 | <1% | 44 | $2K | |
| 87400 | <1% | 282 | $2K | |
| A9585 | Injection, gadobutrol, 0.1 ml | <1% | 194 | $2K |
| 86706 | <1% | 369 | $2K | |
| 36416 | <1% | 465 | $2K | |
| 84132 | <1% | 665 | $2K | |
| 82075 | <1% | 513 | $2K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 304 | $2K |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | <1% | 818 | $2K |
| 86038 | <1% | 321 | $2K | |
| 88360 | <1% | 44 | $2K | |
| 72050 | <1% | 36 | $2K | |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | <1% | 833 | $2K |
| J7510 | Prednisolone oral, per 5 mg | <1% | 485 | $2K |
| 77080 | <1% | 25 | $2K | |
| 90715 | <1% | 81 | $2K | |
| 87493 | <1% | 111 | $2K | |
| 75625 | <1% | 12 | $2K | |
| 73560 | <1% | 43 | $1K | |
| 43450 | <1% | 59 | $1K | |
| 90714 | <1% | 67 | $1K | |
| 86920 | <1% | 178 | $1K | |
| 82043 | <1% | 554 | $1K | |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 1,441 | $1K |
| 82140 | <1% | 226 | $1K | |
| 83655 | <1% | 69 | $1K | |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | <1% | 1,342 | $1K |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 962 | $968.13 |
| 86430 | <1% | 193 | $934.74 | |
| J2920 | Injection, methylprednisolone sodium succinate, up to 40 mg | <1% | 886 | $867.48 |
| 80081 | <1% | 13 | $789.97 | |
| 93226 | <1% | 15 | $734.41 | |
| J2560 | Injection, phenobarbital sodium, up to 120 mg | <1% | 79 | $688.50 |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 37 | $667.83 |
| 84436 | <1% | 156 | $665.84 | |
| 82248 | <1% | 262 | $663.57 | |
| 87522 | Neg quan hep c or qual rna | <1% | 31 | $635.77 |
| 71101 | <1% | 74 | $556.28 | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 14 | $555.16 |
| 74022 | <1% | 46 | $545.19 | |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 2,428 | $529.59 |
| 82010 | <1% | 458 | $486.88 | |
| 94664 | <1% | 91 | $469.24 | |
| 83615 | <1% | 224 | $464.00 | |
| C1726 | Catheter, balloon dilatation, non-vascular | <1% | 182 | $407.38 |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 710 | $398.35 |
| 82330 | <1% | 129 | $364.51 | |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 369 | $359.97 |
| 99152 | <1% | 485 | $359.88 | |
| 93225 | <1% | 15 | $356.81 | |
| 80164 | <1% | 62 | $343.61 | |
| 72072 | <1% | 12 | $334.23 | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 203 | $324.33 |
| 82150 | <1% | 163 | $316.67 | |
| J1940 | Injection, furosemide, up to 20 mg | <1% | 850 | $308.40 |
| 70360 | <1% | 16 | $273.21 | |
| C1751 | Catheter, infusion, inserted peripherally, centrally or midline (other than hemodialysis) | <1% | 458 | $271.39 |
| 72070 | <1% | 14 | $269.62 | |
| 73620 | <1% | 12 | $237.26 | |
| 82784 | <1% | 56 | $226.88 | |
| 82950 | <1% | 44 | $224.81 | |
| 01999 | <1% | 99 | $221.10 | |
| C1776 | Joint device (implantable) | <1% | 12 | $209.56 |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 25 | $207.37 |
| 87425 | <1% | 13 | $181.78 | |
| 84403 | <1% | 13 | $176.71 | |
| 93320 | <1% | 13 | $164.14 | |
| 86308 | <1% | 162 | $156.53 | |
| 87428 | <1% | 14 | $128.78 | |
| 87147 | <1% | 167 | $120.10 | |
| 88173 | <1% | 14 | $120.06 | |
| 86160 | <1% | 29 | $114.98 | |
| 82247 | <1% | 16 | $112.31 | |
| J1756 | Injection, iron sucrose, 1 mg | <1% | 98 | $98.66 |
| 89051 | <1% | 146 | $96.90 | |
| 86664 | <1% | 12 | $95.54 | |
| C1725 | Catheter, transluminal angioplasty, non-laser (may include guidance, infusion/perfusion capability) | <1% | 481 | $93.62 |
| 86364 | <1% | 14 | $92.46 | |
| J3480 | Injection, potassium chloride, per 2 meq | <1% | 206 | $84.46 |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | <1% | 220 | $84.19 |
| 73060 | <1% | 12 | $77.40 | |
| 99153 | Mod sedat endo service >5yrs | <1% | 146 | $73.24 |
| 85347 | <1% | 42 | $70.08 | |
| 84295 | <1% | 44 | $68.99 | |
| J1643 | Injection, heparin sodium (pfizer), not therapeutically equivalent to j1644, per 1000 units | <1% | 141 | $67.99 |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 262 | $65.10 |
| 86787 | <1% | 14 | $62.03 | |
| 87260 | <1% | 21 | $51.06 | |
| J1790 | Injection, droperidol, up to 5 mg | <1% | 476 | $49.52 |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | <1% | 466 | $32.99 |
| J0295 | Injection, ampicillin sodium/sulbactam sodium, per 1.5 gm | <1% | 105 | $30.17 |
| J7999 | Compounded drug, not otherwise classified | <1% | 846 | $28.01 |
| 82365 | <1% | 27 | $25.51 | |
| 86665 | <1% | 24 | $13.10 | |
| 87015 | <1% | 16 | $12.32 | |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 842 | $10.39 |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | <1% | 171 | $5.87 |
| J0360 | Injection, hydralazine hcl, up to 20 mg | <1% | 33 | $4.48 |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | <1% | 483 | $4.03 |
| J1171 | Injection, hydromorphone, 0.1 mg | <1% | 171 | $3.06 |
| C9113 | Injection, pantoprazole sodium, per vial | <1% | 148 | $2.87 |
| J1596 | Injection, glycopyrrolate, 0.1 mg | <1% | 297 | $1.76 |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | <1% | 96 | $0.26 |
| S0028 | Injection, famotidine, 20 mg | <1% | 278 | $0.04 |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 278 | $0.00 |
| Q9957 | Injection, perflutren lipid microspheres, per ml | 0% | 32 | $0.00 |
| J3371 | Injection, vancomycin hcl (mylan), not therapeutically equivalent to j3370, 500 mg | 0% | 68 | $0.00 |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | 0% | 1,533 | $0.00 |
| J0735 | Injection, clonidine hydrochloride, 1 mg | 0% | 12 | $0.00 |
| C1758 | Catheter, ureteral | 0% | 40 | $0.00 |
| J2004 | Injection, lidocaine hcl with epinephrine, 1 mg | 0% | 118 | $0.00 |
| 29515 | 0% | 12 | $0.00 | |
| J2272 | Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg | 0% | 13 | $0.00 |
| C2617 | Stent, non-coronary, temporary, without delivery system | 0% | 68 | $0.00 |
| J2470 | Injection, pantoprazole sodium, 40 mg | 0% | 52 | $0.00 |
| 81000 | 0% | 20 | $0.00 | |
| V2632 | Posterior chamber intraocular lens | 0% | 37 | $0.00 |
| 77001 | 0% | 16 | $0.00 | |
| A9152 | Single vitamin/mineral/trace element, oral, per dose, not otherwise specified | 0% | 42 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialAMOS, ROBERT (VP & CFO)